Patient histories were interrogated extracting clinical characteristics and virological data. Engagement with the Liver Clinics was quantified according to time from referral to first clinic appointment, non-attendance, loss to follow-up and this was correlated with ethnicity, gender, age, CHB phase, presence of advanced disease and geographical distance between patient’s residence and clinics. Results: Of the 204 patients referred, 62% attended the clinics. The mean waiting time from the date of the referral to first attendance was 403 ± 289 days. Of those who had one or more clinic engagements, 47% were lost to follow up

through non-attendance as of the 1st January 2013. Ten patients were classified as cirrhotic in the GP referral, 9 attended clinic, the waiting Dorsomorphin ic50 time to the first attendance was 349 ± 364 days

vs.408 ± 289 in the non-cirrhotic population Topoisomerase inhibitor (p-value: 0.6). The immunological phase of CHB was characterised in 60% of the patients in the referral with 9.3% in immune clearance phase and 1% in immune escape phase. Top 5 ethnicities were Cambodian 24%, Vietnamese 24%, Mainland Chinese 18%, Afghani 7% and Sudanese 5%. Multivariate logistic regression analysis found no association between age, gender and geographical distance from clinic with rates of attendance, loss to follow up and clinic waiting time. Cambodian ethnicity accounted for 42% of all non-attendance, which was significant on multivariate analysis (Table 1. p-value: 0.002). Table 1 Risk Factor for Non-Attendance Beta-Coefficient P-value Age −0.023 0.151 Gender (Male) −0.127 0.745

Immune Clearance Phase −1.414 0.011 Geographical Distance 1.018 0.084 Ethnicity Cambodian 1.435 0.002 Conclusions: This preliminary analysis identifies an association between Cambodian ethnicity and liver clinic non-attendance. The next phase of this study will Etofibrate attempt to further characterise the barriers relevant to each ethnicity. S RAO,1 N KONTORINIS,1 L TARQUINIO,1 J KONG,1 L MOLLISON,2 G MACQUILLAN,3 L ADAMS,3 G JEFFREY,3 S GALHENAGE,2 S NAZARETH,1 L TOTTEN,2 J VALLVE,3 W CHENG1 Departments of Gastroenterology and Hepatology, 1Royal Perth hospital, 2Fremantle Hospital, 3Sir Charles Gairdner Hospital, Perth WA Background: Direct acting antiviral agents (DAAs) – Telaprevir (TVP) and Boceprevir (BOC) have been approved for the treatment of chronic hepatitis C-Genotype 1 patients since April 2013. In the registration trials, renal dysfunction was not observed. Recent preliminary reports suggested that the incidence of renal impairment may be as high as 5%, more common in older patients, and in patients with cirrhosis, diabetes and/or hypertension. We report our early experience with DAAs in 3 tertiary hospitals in patients treated through early access and patient familiarization programs. Aims: To determine the incidence and severity of renal dysfunction in patients treated with DAAs. Methods: Retrospective descriptive analysis of patients treated with DAAs at 3 tertiary centres.